LitCovid-sentences  

PMC:7195088 / 42447-44984 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T312 0-167 Sentence denotes Table 3 Known adverse events of marketed anti-infective and anti-inflammatory drugs mostly provided as off-label treatments in the first phase of the COVID-19 pandemic
T313 168-187 Sentence denotes Drug Adverse events
T314 188-273 Sentence denotes Lopinavir/ritonavir • Hypercholesterolaemia and increased serum triglycerides (3–39%)
T315 274-317 Sentence denotes • Increased γ-glutamyl transferase (10–29%)
T316 318-369 Sentence denotes • Diarrhoea (7–28%; greater with once-daily dosing)
T317 370-403 Sentence denotes • Increased serum ALT (grade 3/4:
T318 404-410 Sentence denotes 1–11%)
T319 411-427 Sentence denotes • Nausea (5–16%)
T320 428-469 Sentence denotes • Upper respiratory tract infection (14%)
T321 470-494 Sentence denotes • Abdominal pain (1–11%)
T322 495-512 Sentence denotes • Vomiting (2–7%)
T323 513-527 Sentence denotes • Fatigue (8%)
T324 528-574 Sentence denotes • Increased serum amylase and/or lipase (3–8%)
T325 575-592 Sentence denotes • Headache (2–6%)
T326 593-610 Sentence denotes • Skin rash (≤5%)
T327 611-636 Sentence denotes • Neutropenia (grade 3/4:
T328 637-642 Sentence denotes 1–5%)
T329 643-657 Sentence denotes • Anxiety (4%)
T330 658-674 Sentence denotes • Insomnia (≤4%)
T331 675-745 Sentence denotes Chloroquine/hydroxychloroquine • Retinopathy (4% of treated patients)a
T332 746-997 Sentence denotes • Other adverse effects with unknown frequency included Stevens-Johnson syndrome, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, leukopenia, thrombocytopenia, abnormal hepatic function tests, acute hepatic ailure, myopathy, bronchospasm
T333 998-1104 Sentence denotes • Risk of prolonged QT interval, further increased when administered with fluoroquinolones or azithromycin
T334 1105-1160 Sentence denotes Tocilizumab • Increased serum ALT (≤36%) and AST (≤22%)
T335 1161-1196 Sentence denotes • Increased LDL cholesterol (9–10%)
T336 1197-1230 Sentence denotes • Injection site reaction (4–10%)
T337 1231-1254 Sentence denotes • Neutropenia (grade 3:
T338 1255-1282 Sentence denotes 2–7% of all adult patients)
T339 1283-1300 Sentence denotes • Headache (1–7%)
T340 1301-1322 Sentence denotes • Hypertension (1–6%)
T341 1323-1339 Sentence denotes • Dizziness (3%)
T342 1340-1362 Sentence denotes • Hypothyroidism (<2%)
T343 1363-1384 Sentence denotes • Abdominal pain (2%)
T344 1385-1421 Sentence denotes • Oral mucosa or gastric ulcers (2%)
T345 1422-1595 Sentence denotes • Infections due to Pneumocystis, Mycobacterium tuberculosis and varicella zoster have been reported after tocilizumab, but their prevalence has not been clearly established
T346 1596-1640 Sentence denotes Anakinra • Injection site reactionb (24–71%)
T347 1641-1754 Sentence denotes • Antibody development (up to 50% of the patients but no correlation of antibody development and adverse effects)
T348 1755-1787 Sentence denotes • Headache and vomiting (12–14%)
T349 1788-1809 Sentence denotes • Arthralgia (10–12%)
T350 1810-1826 Sentence denotes • Fever (10–12%)
T351 1827-1921 Sentence denotes • Haematologic disorder including eosinophilia, leukopenia and change in platelet count (2–9%)
T352 1922-1951 Sentence denotes • Nausea and diarrhoea (7–8%)
T353 1952-1979 Sentence denotes • Serious infectionc (2–3%)
T354 1980-2113 Sentence denotes Off-label drugs mostly provided in Italy during the first phase of the COVID-19 pandemic according to the authors' direct experience.
T355 2114-2243 Sentence denotes ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID-19, coronavirus disease 2019; LDL, low-density lipoprotein.
T356 2244-2384 Sentence denotes a Serum concentration dependent adverse effect; early changes are generally reversible but may progress despite discontinuation if advanced.
T357 2385-2453 Sentence denotes b Injection site reactions were considered serious in 2–3% of cases.
T358 2454-2537 Sentence denotes c Serious infections included cellulitis, pneumonia, and bone and joint infections.